Evolent Health (NYSE:EVH) Earns Buy Rating from Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Evolent Health (NYSE:EVH - Free Report) in a research report released on Wednesday,Benzinga reports. They currently have a $15.00 price target on the technology company's stock.

Several other equities research analysts have also commented on EVH. Stephens decreased their price target on Evolent Health from $16.00 to $12.00 and set an "equal weight" rating on the stock in a research note on Tuesday, January 21st. Truist Financial decreased their price target on Evolent Health from $20.00 to $15.00 and set a "buy" rating on the stock in a research note on Wednesday, January 22nd. UBS Group decreased their price target on Evolent Health from $27.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, January 16th. JPMorgan Chase & Co. decreased their price target on Evolent Health from $15.00 to $13.00 and set an "overweight" rating on the stock in a research note on Tuesday, January 28th. Finally, Oppenheimer decreased their price target on Evolent Health from $28.00 to $18.00 and set an "outperform" rating on the stock in a research note on Friday, January 24th. One equities research analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $17.92.

Evolent Health Stock Performance

EVH traded up $0.10 during trading on Wednesday, reaching $10.07. The company's stock had a trading volume of 1,745,560 shares, compared to its average volume of 2,244,315. Evolent Health has a 52-week low of $9.45 and a 52-week high of $35.00. The company's fifty day moving average price is $10.86 and its 200-day moving average price is $19.28. The company has a market capitalization of $1.17 billion, a price-to-earnings ratio of -11.06 and a beta of 1.45. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Pilgrim Partners Asia Pte Ltd acquired a new position in Evolent Health in the 4th quarter valued at $26,000. R Squared Ltd acquired a new position in Evolent Health in the 4th quarter valued at $31,000. AlphaQuest LLC raised its holdings in Evolent Health by 21,650.0% in the 4th quarter. AlphaQuest LLC now owns 3,045 shares of the technology company's stock valued at $34,000 after acquiring an additional 3,031 shares during the last quarter. Covestor Ltd raised its holdings in Evolent Health by 138.1% in the 3rd quarter. Covestor Ltd now owns 1,424 shares of the technology company's stock valued at $40,000 after acquiring an additional 826 shares during the last quarter. Finally, GAMMA Investing LLC raised its holdings in Evolent Health by 5,365.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company's stock valued at $45,000 after acquiring an additional 1,556 shares during the last quarter.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.